SCP-3753
Safe
~
medium confidence
SCP-3753
Expected annual
$2.0M
One-time setup
$2.5M
Annual recurring
$2.0M
Personnel
12
Initial containment and basic research infrastructure are moderate but biosafety, medical monitoring, and ongoing staff/security are the main recurring cost drivers; estimated first-year one-time costs ~ $2.5M with annual operations ~ $2.0M.
One-Time Capital Costs
Total: $2.5M
Annual Recurring Costs
Total: $2.0M/yr
Cost Scenarios
📊
Baseline
(baseline)
$2.0M/yr
Normal year with routine operations, regular monitoring, and no major incidents.
routine_operations
no_security_incidents
🚨
Minor Incident
$2.0M/yr
Localized equipment failure, small contamination event, or single-subject adverse event requiring investigation and limited remediation.
equipment_failure
localized_contamination
single_injury
🚨
Major Breach
$3.0M/yr
Security breach or containment failure causing multiple injuries/exposures and public exposure requiring heavy remediation, legal action, and PR.
security_breach
multiple_exposures
public_disclosure
🚨
Research Breakthrough Requiring Scale Up
$3.5M/yr
Leadership approves scaling to clinical development/manufacturing after promising results, triggering multi-year program costs.
therapeutic_potential_confirmed
leadership_approval
Personnel
12 total
| Role | Count | Notes |
|---|---|---|
| Medical Officer / Nurse / Technician | 3 | [#7, #8] One on-call physician plus nurses/techs for monitoring, resuscitation, and experiment support. |
| Research Scientist | 3 | [#9, #13] Microbiologists/pathologists/behavioral researchers to study mechanism and analyze samples. |
| Lab Technician | 2 | [#9, #13] Lab technicians for sample processing, sequencing prep, and routine BSL work. |
| Security Officer / MTF Agent | 4 | [#10] Armed/unarmed guards and escorts for 24/7 access control, vetting, and material transport. |
Confidence Notes
Analyst notes provide detailed line items and ranges, enabling reasonable mid-point estimates; uncertainty remains around biosafety upgrade choices, the decision to pursue clinicalization, and low-frequency high-cost events, so confidence is not high.